About Adlego Biomedical
Adlego Biomedical is a Healthcare company based in Uppsala (Sweden) founded in 2005, and was acquired by Scantox in September 2022. In-vivo pharmacology and toxicology services are provided for drug candidates. Adlego Biomedical offers products and services including Webhosting, Domæner, Cloud Server, Virtual Server, and Betalingsløsning. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified. Its legal entity is A/S ScanNet.
Company details
Adlego Biomedical was founded in 2005 and is based in Uppsala, Sweden, within the biomedical sector. In vivo studies on safety, efficacy, metabolism, and pharmacokinetics of hit and lead compounds are conducted. Services encompass DMPK assessments, acute and repeated-dose toxicity evaluations, haematology, clinical chemistry, and histopathology analyses. Effect models for cancer and inflammation are utilized, alongside behavioural and biocompatibility testing, surgical procedures, and catheterization capabilities.
Products & Services of Adlego Biomedical
Adlego Biomedical offers a comprehensive portfolio of products and services, including Webhosting, Domæner, Cloud Server, Virtual Server, and Betalingsløsning.
Provides online storage and management for websites.
Handles registration and maintenance of domain names.
Offers scalable servers for data storage and applications.
Delivers virtual computing environments for businesses.
Facilitates secure online payment processing systems.
Funding Insights of Adlego Biomedical
- Total Rounds 1
- Last Round Grant — $898,783
- First Round $898,783
(Apr 2020)
- Investors Count 1
All 1 funding rounds of Adlego Biomedical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $898,783 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Adlego Biomedical
Adlego Biomedical has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Scantox and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Laboratory focused on providing pharmacology, toxicology, and histopathology services | 1977 | scantox.com | Lille Skensved, Denmark |
Investor details for Adlego Biomedical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Adlego Biomedical
3 dated milestones of Adlego Biomedical across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Adlego Biomedical is founded.
- Funding First funding round of $899K.
- Exit Acquired by Scantox.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adlego Biomedical
Complete news archive for Adlego Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adlego Biomedical
Adlego Biomedical was founded in 2005 and raised its 1st funding round 15 years after it was founded.
Adlego Biomedical is headquartered in Uppsala, Sweden. It is registered at Uppsala, Uppsala County, Sweden.
Adlego Biomedical was founded in 2005 and is based in Uppsala, Sweden, within the biomedical sector. In vivo studies on safety, efficacy, metabolism, and pharmacokinetics of hit and lead compounds are conducted. Services encompass DMPK assessments, acute and repeated-dose toxicity evaluations, haematology, clinical chemistry, and histopathology analyses. Effect models for cancer and inflammation are utilized, alongside behavioural and biocompatibility testing, surgical procedures, and catheterization capabilities.
Adlego Biomedical offers Webhosting, Domæner, Cloud Server, Virtual Server, and Betalingsløsning.
Adlego Biomedical has 2 investors. Key investors include Scantox, and European Union.
Adlego Biomedical operates through A/S Scannet.
Yes. Adlego Biomedical was acquired by Scantox in September 2022.